As a major player in strengthening the traditional Chinese medicine sector, the company has actively pursued strategic acquisitions. In January 2023, it acquired a 28 percent stake in Kunming, Yunnan province-based KPC Pharmaceuticals, completing the first A-share acquisition of its kind to qualify as a major asset restructuring.

In March 2025, it followed with another landmark deal, acquiring a 28 percent stake in Tianjin-based Tasly, marking the second such transaction during the 14th Five-Year Plan. 

The three enterprises now form a complementary structure to build differentiated competitiveness through deepened collaboration. CR Sanjiu positions itself with consumer healthcare at the core to become an industry leader, while Tasly focuses on prescription drugs, and KPC Pharmaceuticals leverages its flagship TCM products to target the silver economy.

Looking ahead, as the company prepares to conclude the 14th Five-Year Plan and map out the 15th, CR Sanjiu said it will continue to shoulder its responsibility as a centrally administered State-owned enterprise, sharpen its core business focus, and accelerate innovation-driven transformation. By doing so, the drugmaker aims to offer "Chinese wisdom" and "Chinese solutions" for human well-being, it said.

lijiaying@chinadaily.com.cn